Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mish's Global Economic Trend Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Little Joe who wrote (100493)	8/6/2009 10:58:29 PM
From: Casaubon	Read Replies (4) \| Respond to of 116555

expense is a problem that the industry faces. I can tell you for sure that competition is fierce. There are many clever people investigating different mechanisms of disease progression. The pace of research is really accelerating. However, the failure rate is extremely high. This aspect is under intense scrutiny. If we have assays that are predictive of common failure events, then we can circumvent many of the very expensive clinical trials of drug candidates that don't ever make it to the market. This is definitely a source for improvement in the industry; which could ultimately lower the cost of medication. As I mentioned in another post, there is an 80-90% failure, once a project makes it to the point of clinical trials. And that only occurs after an average of ten years of research, prior to human trials. While the ten years of research is a massive and expensive undertaking, it is actually the subsequent human clinical trials which represents the lions share of cost. The emerging attitude in the industry is to design clinical trials which force a failure as quick as possible to avoid unnecessary and even more costly trials. It's a heart wrenching business and requires insane perseverance.